概要
目 的
研究不同分期下左右半结直肠神经内分泌肿瘤 (NEN) 的生存差异。
创新点
左右半结直肠腺癌的生存差异已得到深入研究, 而结直肠NEN作为一罕见病理类型, 其左右半的生存差异尚缺乏研究。 本研究旨在明确这一问题。
方 法
选取 SEER 数据库中 1988~2014 年经病理确诊的结直肠 NEN 患者进行回顾性研究。 多因素 Cox 回归分析比较左右半结直肠 NEN 的生存差异。
结 论
相比于左半结直肠 NEN, 右半结肠 NEN 具有显著升高的死亡风险。 而直肠与盲肠 NEN 是不同分期下左右半结直肠 NEN 生存差异的主要影响因素。
This is a preview of subscription content, log in via an institution to check access.
References
Benson AB III, Venook AP, Cederquist L, et al., 2017. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(3):370–398. https://doi.org/10.6004/jnccn.2017.0036
Cesar D, Zanatto RM, da Silva MV, et al., 2013. Colon and rectum neuroendocrine tumors: experience of the National Cancer Institute in Brazil. Arq Bras Cir Dig, 26(1): 36–39. https://doi.org/10.1590/S0102-67202013000100008
Cives M, Strosberg JR, 2018. Gastroenteropancreatic neuro-endocrine tumors. CA Cancer J Clin, 68(6):471–487. https://doi.org/10.3322/caac.21493
Clark OH, Benson AB III, Berlin JD, et al., 2009. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw, 7(7):712–747. https://doi.org/10.6004/jnccn.2009.0050
Dasari A, Shen C, Halperin D, et al., 2017. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol, 3(10):1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589
Garcia-Carbonero R, Sorbye H, Baudin E, et al., 2016. ENETS consensus guidelines for high-grade gastroenteropancre-atic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology, 103(2):186–194. https://doi.org/10.1159/000443172
Gu Q, Lin YM, Cen L, et al., 2019. Endoscopic ultrasonog-raphy is useful in the diagnosis and treatment of rectal neuroendocrine neoplasms: a case series. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(10):861–864. https://doi.org/10.1631/jzus.B1900168
Jernvall P, Mäkinen MJ, Karttunen TJ, et al., 1999. Microsat-ellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer, 35(2): 197–201. https://doi.org/10.1016/S0959-8049(98)00306-2
Meguid RA, Slidell MB, Wolfgang CL, et al., 2008. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol, 15(9):2388–2394. https://doi.org/10.1245/s10434-008-0015-y
Mik M, Berut M, Dziki L, et al., 2017. Right- and left-sided colon cancer—clinical and pathological differences of the disease entity in one organ. Arch Med Sci, 13(1):157–162. https://doi.org/10.5114/aoms.2016.58596
Mitry E, Baudin E, Ducreux M, et al., 1999. Treatment of poorly differentiated neuroendocrine tumours with etopo-side and cisplatin. Br J Cancer, 81(8):1351–1355. https://doi.org/10.1038/sj.bjc.6690325
Modlin IM, Lye KD, Kidd M, 2003. A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97(4):934–959. https://doi.org/10.1002/cncr.11105
Patta A, Fakih M, 2011. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res, 31(3):975–978.
Popat S, Hubner R, Houlston RS, 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 23(3):609–618. https://doi.org/10.1200/JCO.2005.01.086
Portale TR, Branca A, Pesce A, et al., 2012. Neuroendocrine carcinoma of colon and rectum: a rare neoplasia with a poor prognosis. Minerva Chir, 67(3):283–284.
Price TJ, Beeke C, Ullah S, et al., 2015. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer, 121(6):830–835. https://doi.org/10.1002/cncr.29129
Sahnane N, Furlan D, Monti M, et al., 2015. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer, 22(1): 35-45. https://doi.org/10.1530/ERC-14-0410
Snaebjornsson P, Jonasson L, Jonsson T, et al., 2010. Colon cancer in Iceland—a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int J Cancer, 127(11): 2645–2653. https://doi.org/10.1002/ijc.25258
Starzyńska T, Deptała A, Królicki L, et al., 2013. Colorectal neuroendocrine neoplasms—management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol, 64(6):494–504. https://doi.org/10.5603/EP.2013.0032
Starzyńska T, Londzin-Olesik M, Bałdys-Waligórska A, et al., 2017. Colorectal neuroendocrine neoplasms—management guidelines (recommended by the Polish Network of Neu-roendocrine Tumours). Endokrynol Pol, 68(2):250–260. https://doi.org/10.5603/EP.2017.0019
Yao JC, Hassan MM, Phan A, et al., 2008. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26(18):3063–3072 https://doi.org/10.1200/JCO.2007.15.4377
Author information
Authors and Affiliations
Contributions
Ge-han XU collected and analyzed the data, and wrote the manuscript. Hua-wei ZOU and Ashley B. GROSSMAN contributed to the study design, data analysis, writing and editing of the manuscript. All authors have read and approved the final manuscript and, therefore, had full access to all the data in the study and take responsibility for the integrity and security of the data.
Corresponding author
Ethics declarations
Ge-han XU, Hua-wei ZOU, and Ashley B. GROSSMAN declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Project supported by the Beijing Medical and Health Foundation (No. YWJKQ4008), China
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Xu, Gh., Zou, Hw. & Grossman, A.B. Difference in survival between right- versus left-sided colorectal neuroendocrine neoplasms. J. Zhejiang Univ. Sci. B 20, 933–939 (2019). https://doi.org/10.1631/jzus.B1900210
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1900210